Dong-A ST
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Dong-A ST makes prescription medicines, drugs that require a doctor's order, along with medical devices and related health-care products, supplying hospitals, clinics, and pharmacies in Korea.
It is listed on KOSPI, Korea's main stock exchange. The company's portfolio includes several drugs it developed in-house, such as treatments for erectile dysfunction, gastrointestinal motility, and diabetes, and it manufactures products at three domestic facilities. Its active research pipeline focuses on new drugs for metabolic diseases including diabetes, obesity, and a liver condition known as MASH.
Summary is AI-generated and may contain errors · figures from DART filings
Dong-A ST was spun off from Dong-A Socio Holdings (formerly Dong-A Pharmaceutical) as an independent prescription-drug business.
Dong-A ST in five facts
What does Dong-A ST do?
Dong-A ST makes prescription medicines, drugs that require a doctor's order, along with medical devices and related health-care products, supplying hospitals, clinics, and pharmacies in Korea.
Where is Dong-A ST listed and in which sector?
Dong-A ST (Korean name: 동아에스티) trades under KRX code 170900 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Dong-A ST?
Its market capitalisation was US$260.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Dong-A ST's latest annual revenue and operating profit?
For fiscal year 2025, Dong-A ST reported revenue of US$610.4M, operating profit of US$470.4K and a net loss of US$28.4M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 15.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Operating results (preliminary) (fair disclosure)
Dong-A ST filed provisional (unaudited) separate results for Q2 2026: revenue of US$142M (+17.2% year on year), operating profit of US$7.42M (+170.4% year on year) and net income of US$5.47M (from a loss a year earlier).
Earnings · Jul 27 - Operating results (preliminary) (fair disclosure)
Dong-A ST filed provisional (unaudited) separate results for Q1 2026: revenue of US$127M (+10.7% year on year), operating profit of US$7.31M (+53.7% year on year) and net income of US$3.9M (+16.7% year on year).
Earnings · Apr 27 - Stock dividend decisionDividend · Feb 23
- Cash/in-kind dividend decision
Dong-A ST declared a cash dividend of US$0.48 per share.
Dividend · Feb 23 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Dong-A ST reported consolidated results for FY2025: revenue of US$560M (+15.9% year on year), operating profit of US$436K (from a loss a year earlier) and a net loss of US$30M.
Earnings · Feb 23 - Operating results (preliminary) (fair disclosure)
Dong-A ST filed provisional (unaudited) separate results for Q4 2025: revenue of US$137M (+22.6% year on year) and an operating loss of US$379K (from a profit a year earlier).
Earnings · Feb 9 - Treasury share disposal: results reportTreasury Shares · Jan 19
- Material event report (treasury share disposal)Treasury Shares · Jan 16